Form 4: Amphastar Pharmaceuticals Director Gayle Deflin Acquires Shares and Stock Options
SEC Form 4 Filing
Director Gayle Deflin of Amphastar Pharmaceuticals reports acquisition of common stock and stock options.
Summary
- On June 3, 2024, Gayle Deflin, a director at Amphastar Pharmaceuticals, acquired 3,076 shares of common stock and disposed of 5,792 shares.
- These shares were acquired at a price of $0.
- Following these transactions, Deflin directly owns 5,792 shares of common stock.
- Deflin also acquired stock options for 6,864 shares at an exercise price of $42.25, expiring on June 3, 2034.
- These options also vest on June 3, 2025.
- The reported shares are represented by restricted stock units (RSUs), all of which vest on June 3, 2025.
Sentiment
Score: 5
Explanation: The sentiment is neutral as it's a standard disclosure of insider transactions. There's no indication of positive or negative implications for the company.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company insiders.
Stakeholder Impact
- The transactions may have a minor impact on shareholders as they provide insight into the actions of a company director.
Key Dates
| Date | Description |
|---|---|
| 06/03/2024 | Date of transaction: Acquisition and disposition of common stock, and acquisition of stock options. |
| 06/03/2025 | Vesting date for RSUs and stock options. |
| 06/03/2034 | Expiration date for stock options. |
| 06/05/2024 | Date of signature for the report. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.